Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers by Abdel-Fatah, T et al.
1	  
	  
Adverse prognostic and predictive significance of low DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) expression in early stage breast cancers 
 
Tarek Abdel-Fatah1, Arvind Arora2, Devika Agarwal3, Paul Moseley1, Christina Perry2, 
Nicola Thompson1, Andrew Green4, Emad Rakha4, Stephen Chan1, Carlos Caldas5, Graham 
Ball3, Ian O Ellis4 and Srinivasan Madhusudan 1, 2*. 
 
1Department of Oncology, Nottingham University Hospitals, Nottingham NG51PB, UK.  
2Academic Unit of Oncology, Division of  Cancer and Stem Cells, School of Medicine, 
University of Nottingham, Nottingham University Hospitals, Nottingham NG51PB, UK.  
3 School of Science and Technology, Nottingham Trent University, Clifton Campus, 
Nottingham NG11 8NS, UK.  
4Department of Pathology,  Division of  Cancer and Stem Cells, School of Medicine, 
University of Nottingham, Nottingham University Hospitals, Nottingham NG51PB, UK.  
5Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, 
Cambridge CB2 0RE, UK.  
 
Running title: DNA-PKcs in breast cancer 
Disclosure: The authors have declared no conflicts of interest. 
Word count:  
 
2	  
	  
 
* Corresponding author: 
 
Academic Unit of Oncology 
Division of Cancer and Stem Cells 
School of Medicine 
University of Nottingham 
Nottingham University Hospitals 
Nottingham NG51PB 
UK 
Telephone: +44(0)115 823 1850 
Fax: +44(0)115 823 1849 
E-Mail: srinivasan.madhusudan@nottingham.ac.uk 
  
3	  
	  
ABSTRACT 
Background: DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a serine 
threonine kinase belonging to the PIKK family (phosphoinositide 3-kinase-like-family of 
protein kinase), is a critical component of the non-homologous end joining (NHEJ) pathway 
required for the  repair of DNA double strand breaks. DNA-PKcs may be involved in breast 
cancer pathogenesis. 
Methods: We evaluated clinicopathological significance of DNA-PKcs protein expression in 
1161 tumours and DNA-PKcs mRNA expression in 1950 tumours. We correlated DNA-PKcs 
to other markers of aggressive phenotypes, DNA repair, apoptosis and cell cycle regulation.  
Results:  Low DNA-PKcs protein expression was associated with higher tumour grade, 
higher mitotic index, tumour de-differentiation and tumour type (ps<0.05). Absence of 
BRCA1, low XRCC1, low SMUG1, low APE1 and low Polβ were also more likely in low 
DNA-PKcs expressing tumours (ps<0.05). Low DNA-PKcs protein expression was 
significantly associated with worse breast cancer specific survival (BCCS) in univariate and 
multivariate analysis (ps<0.01). At the mRNA level, low DNA-PKcs was associated with 
PAM50.Her2 and PAM50.LumA molecular phenotypes (ps<0.01) and poor BCSS. In 
patients with ER positive tumours who received endocrine therapy, low DNA-PKcs (protein 
and mRNA) was associated with poor survival. In ER negative patients, low DNA-PKcs 
mRNA remains significantly associated with adverse outcome. 
Conclusions:   Our study suggests that low DNA-PKcs expression may have prognostic and 
predictive significance in breast cancers. 
 
 
 
4	  
	  
INTRODUCTION 
 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a serine threonine kinase 
belonging to the PIKK family (phosphoinositide 3-kinase-like-family of protein kinase), is an 
essential component of the non-homologous end joining (NHEJ) DNA repair pathway 
{Kong, 2011 #219;Neal, 2011 #220;Hill, 2010 #221;Meek, 2008 #224;Salles, 2006 
#225;Collis, 2005 #226}. NHEJ is central to the repair of DNA double strand breaks (DSBs) 
that may be generated throughout the cell cycle. DNA-PKcs is recruited to the sites of DSBs 
by Ku70/Ku80 heterodimer which then leads to its auto-phosphorylation at Ser2056, resulting 
in a conformational change that promote DSB repair function of DNA-PKcs in cells. In 
addition, phosphorylation at Thr2609 by ATM (ataxia telangiectasia mutated) or ATR (ataxia 
telangiectasia-Rad3-related) kinases also regulate biological functions of DNA-PKcs {Kong, 
2011 #219;Neal, 2011 #220;Hill, 2010 #221;Meek, 2008 #224;Salles, 2006 #225;Collis, 
2005 #226}. Besides an essential role in NHEJ, DNA-PKcs may be involved in cell cycle 
control, telomere maintenance, transcriptional regulation and p53 dependent apoptosis in 
cells {Kong, 2011 #219;Neal, 2011 #220;Hill, 2010 #221;Meek, 2008 #224;Salles, 2006 
#225;Collis, 2005 #226}. 
 
DNA-PKcs deficiency results in severe combined immunodeficiency (SCID) in mammals 
{van der Burg, 2009 #218}. The role of DNA-PKcs in carcinogenesis, however, is less well 
characterised.  Single nucleotide polymorphisms in the DNA-PKcs gene may be associated 
with increased risk of bladder {Wang, 2008 #239} and hepatocellular cancer {Long, 2011 
#240} development. In lung cancers, similarly, polymorphisms in the DNA-PKcs gene appear 
to confer altered cancer susceptibility {Hu, 2008 #242}.  Somatic mutations in the DNA-PKcs 
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gene have been described in breast and pancreatic cancers {Wang, 2008 #248}.  DNA-PKcs 
activity appears to be lower in patients with cancer compared to normal controls, implying a 
role for impaired DNA-PKcs in cancer risk and development. Interestingly, in established 
human tumours, the situation is far more complex. In tumours such as nasopharyngeal 
carcinoma, oesophageal cancer, colorectal cancer and lymphoid malignancies DNA-PKcs is 
overexpressed and associated with poor prognosis. On the other hand, in gastric and ovarian 
cancers, low expression of DNA-PKcs is linked to adverse outcomes in patients (reviewed in 
{Hsu, 2012 #253}). A large body of pre-clinical cancer cell lines or xenograft models based 
studies suggests that DNA-PKcs down-regulation or inhibition by small molecule inhibitors 
is associated with sensitization to chemotherapy and radiotherapy {Hsu, 2012 #253;Zhuang, 
2011 #254;Du, 2010 #256;Shinohara, 2005 #257}.  
 
The clinicopathological significance of DNA-PKcs expression in breast cancer is unknown. 
Our hypothesis is that altered DNA-PKcs expression may be associated with aggressive 
tumour biology and adversely impact upon clinical outcomes. In the current study we have 
investigated DNA-PKcs protein as well as mRNA expression in large cohorts of primary 
breast cancers. We demonstrate that low DNA-PKcs expression is associated with an 
aggressive phenotype and poor clinical outcome in patients.  
 
METHODS 
 
Patients: The study was performed in a consecutive series of 1650 patients with primary 
invasive breast carcinoma who were diagnosed from 1986 to 1999 and entered into the 
Nottingham Tenovus Primary Breast Carcinoma series. Patient demographics are summarised 
in supplementary table S1. This is a well-characterized series of patients with long-term 
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follow-up that have been investigated in a wide range of biomarker studies.  All patients were 
treated in a uniform way in a single institution with standard surgery (mastectomy or wide 
local excision) with radiotherapy. Prior to 1989, patients did not receive systemic adjuvant 
treatment (AT). After 1989, AT was scheduled based on prognostic and predictive factor 
status, including Nottingham Prognostic Index (NPI), oestrogen receptor-α (ER-α) status, and 
menopausal status. Patients with NPI scores of <3.4 (low risk) did not receive AT. In pre-
menopausal patients with NPI scores of ≥3.4 (high risk), classical Cyclophosphamide, 
Methotrexate, and 5-Flurouracil (CMF) chemotherapy was given; patients with ER-α positive 
tumours were also offered endocrine therapy. Postmenopausal patients with NPI scores of 
≥3.4 and ER-α positivity were offered endocrine therapy, while ER-α negative patients 
received classical CMF chemotherapy. 
Median follow up was 111 months (range 1 to 233 months).  Survival data, including overall 
survival, disease-free survival (DFS), and development of loco-regional and distant 
metastases (DM), was maintained on a prospective basis.  DFS was defined as the number of 
months from diagnosis to the occurrence of local recurrence, local lymph node (LN) relapse 
or DM relapse.  Breast cancer specific survival (BCSS) was defined as the number of months 
from diagnosis to the occurrence of BC related-death. Local recurrence free survival (LRS) 
was defined the number of months from diagnosis to the occurrence of local recurrence. DM-
free survival was defined as the number of months from diagnosis to the occurrence of DM 
relapse.  Survival was censored if the patient was still alive at the time of analysis, lost to 
follow-up, or died from other causes. 
Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et 
al{McShane, 2005 #261}, were followed throughout this study.  Ethical approval was 
obtained from the Nottingham Research Ethics Committee (C202313).  
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Construction of Tissue Microarray (TMA): TMAs were constructed. Area-specialised 
histopathologists identified and marked formalin-fixed paraffin-embedded tissue blocks 
containing tumour tissue on haematoxylin and eosin stained slides.  Two replicate 0.6mm 
cores from the centre and periphery of the tumours were taken and arrayed into a recipient 
paraffin block using a tissue puncher/arrayer (Beecher Instruments, Silver Spring, MD, 
USA). Four micron sections of the tissue array block were cut and placed on Superfrost Plus 
slides for immunohistochemical staining.   
Immunohistochemistry (IHC): The TMAs were immunohistochemically profiled for DNA-
PKcs and other biological antibodies (Supplementary Table S2) as previously described 
{Abdel-Fatah, 2014 #269;Abdel-Fatah, 2014 #270;Abdel-Fatah, 2013 #272}. 
Immunohistochemical staining was performed using the Thermo Scientific Shandon 
Sequenza chamber system (REF: 72110017), in combination with the Novolink Max Polymer 
Detection System (RE7280-K: 1250 tests), and the Leica Bond Primary Antibody Diluent 
(AR9352), each used according to the manufacturer’s instructions (Leica Microsystems).  
The tissue slides were deparaffinised with xylene and then rehydrated through five decreasing 
concentrations of alcohol (100%, 90%, 70%, 50% and 30%) for two minutes each. Pre-
treatment antigen retrieval was performed on the TMA sections using sodium citrate buffer 
(pH 6.0), heated for 20 minutes at 950C in a microwave (Whirpool JT359 Jet Chef 1000W). 
The slides were incubated for one hour with the primary mouse monoclonal anti-DNA PKcs 
antibody clone 3H6 (ab110034, Abcam, Cambridge, UK) at a dilution of 1:1000.  
To validate the use of TMAs for immunophenotyping, full-face sections of 40 cases were 
stained and protein expression levels of DNA-PKcs antibodies were compared.  The 
concordance between TMAs and full-face sections was excellent (k = 0.8). Positive and 
negative (by omission of the primary antibody and IgG-matched serum) controls were 
included in each run.  
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Evaluation of immunohistochemical staining: The tumour cores were evaluated by 
specialist pathologists and oncologists blinded to the clinico-pathological characteristics of 
patients. Whole field inspection of the core was scored and intensities of nuclear staining 
were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = 
strong staining. The percentage of each category was estimated (0-100%).  H-score (range 0-
300) was calculated by multiplying intensity of staining and percentage staining. H-score in a 
range of 0 – 300 was generated. The median H-score of 100 was taken as the cut-off and low 
DNA-PKcs expression was classed as H-score of ≤ 200 and >200 was classed as high for 
DNA-PKcs expression.  Not all cores within the TMA were suitable for IHC analysis as some 
cores were missing or lacked tumour. HER2 expression was assessed according to the new 
ASCO/CAP guidelines using IHC and fluorescnce in situ hybridisation (FISH) {Wolff, 2013 
#395}. 
Breast cancer cell lines and Western blot analysis: MCF-7, MDA-MB-231 MDA-MB-436 
breast cancer cell lines were purchased from ATCC and grown in RPMI medium 
supplemented with 10% FBS and 1% penicillin/streptomycin. Western blot analysis was 
performed as described previously {Sultana, 2013 #276}.  
DNA-PKcs mRNA expression: The METABRIC (Molecular Taxonomy of Breast Cancer 
International Consortium) cohort comprising a cohort of 1980 breast cancer samples (Curtis 
et al.) was evaluated for DNA-PKcs mRNA expression.  Patient demographics are 
summarized in supplementary Table S3 of supporting information. ER positive and/or 
lymphnode negative patients did not receive adjuvant chemotherapy.  ER negative and/or 
lymphnode positive patients received adjuvant chemotherapy.  RNA was extracted from fresh 
frozen tumours and subjected to transcriptional profiling on the Illumina HT-12 v3 platform.  
The data was pre-processed and normalized as described previously {Curtis, 2012 #404}. 
DNA-PKcs expression was investigated in this data set.  The Chi-square test was used for 
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testing association between categorical variables was fitted to the data using as endpoint 
breast cancer specific death. X-tile (version 3.6.1, Yale University, USA) was used to identify 
a cut-off in gene expression values to divide the population in to high/low  subgroups prior to 
Kaplan Meier Survival analysis.  Kaplan Meier curves were constructed in SPSS Statistics 
(Version 21) for DNA-PKcs (probe-ILMN_2253648) and the log score calculated. 
Statistical analyses: Data analysis was performed using SPSS (SPSS, version 17 Chicago, 
IL). Where appropriate, Pearson’s Chi-square, Fisher’s exact, χ2 for trend, Student’s t and 
ANOVAs one way tests were performed using SPSS software (SPSS, version16 Chicago, 
IL).  Cumulative survival probabilities were estimated using the Kaplan–Meier method. 
Differences between survival rates were tested for significance using the log-rank test.  
Multivariate analysis for survival was performed using the Cox hazard model. The 
proportional hazards assumption was tested using standard log-log plots.  Each variable was 
assessed in univariate analysis as a continuous and categorical variable and the two models 
were compared using an appropriate likelihood ratio test.  Hazard ratios (HR) and 95% 
confidence intervals (95% CI) were estimated for each variable.  All tests were two-sided 
with a 95% CI. P values for each test were adjusted with Benjamini and Hochberg multiple 
P-value adjustment and an adjusted p value of <0.05 was considered significant. 
 
RESULTS 
 
DNA-PKcs protein expression in breast cancer (Whole cohort): We first investigated the 
expression of DNA-PKcs in a panel of breast cancer cell lines. As shown in Figure 1A, robust 
expression of DNA-PKcs was evident in MCF-7, MDA-MB-231 and MDA-MB-436 breast 
cancer cells. We then proceeded to immunohistochemical investigation.  
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A total of 1161 tumours were suitable for DNA-PKcs protein expression analysis (Table 1).  
404/1161 (34.8%) had low DNA-PKcs expression compared to 757/1161 (65.2%) tumours 
that had high DNA-PKcs expression (Figure 1A). Low DNA-PKcs expression was associated 
with higher tumour grade (p=0.001), higher mitotic index (p<0.000001), tumour de-
differentiation (p=0.008) and tumour type (p=0.031) (Table 1). ER negative tumours were 
more likely to have low DNA-PKcs expression (p=0.021), as were AR negative tumours 
(p=0.00001). DNA-PKcs expression was also associated with cytokeratin 18 (CK18) 
(p=0.007) and cytokeratin 19 (CK19) (p=0.002). Low p21 and low TOPO2A and low p21 
was likely in low DNA-PKcs expressing tumours (p<0.05). Absence of BRCA1, low 
XRCC1, low SMUG1, low APE1, low FEN1 and low Polβ were also more likely associated 
with low DNA-PKcs expression in tumours (p<0.05).   
 
Low DNA-PKcs expression was significantly associated with worse breast cancer specific 
survival (BCCS) (p=006) and disease free survival (p<0.0001) (Figure 1B & C).  On 
multivariate cox regression analysis, low DNA-PKcs remains independently associated with 
BCSS (p<0.001) and DFS (p<0.001), alongside tumour stage, grade and size (Table 4).   
Taken together the data suggests that low DNA-PKcs may be associated with aggressive 
breast cancer. We then proceed to conduct sub-group analysis in ER positive, as well as in 
ER negative, breast cancers. 
 
DNA-PKcs protein expression in ER positive breast cancer: A total of 835 tumours were 
suitable for analysis. 272/835 of patients (32.5%) with ER positive breast cancer were 
classified as having low DNA-PKcs expression. Univariate associations between APE1 
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expression and clinicopathological variables are shown in Table 2.  Low DNA-PKcs 
expression was associated higher tumour grade (p=0.021), higher mitotic index (p=0.013), 
tumour de-differentiation (p=0.011) and tumour type (p=0.018). AR- tumours were more 
likely to have low DNA-PKcs expression (p=0.001). Low DNA-PKcs expression was also 
associated low TOP2A (p=0.002).  DNA repair protein levels associated with low DNA-
PKcs expression included absent BRCA1 (p=0.045), XRCC1 (p<0.0001), SMUG1 
(p<0.0001), APE1 (p<0.0001) and polβ (p<0.0001) (Table 2).  In the ER positive cohort, low 
DNA-PKcs expression was significantly associated with worse breast cancer specific survival 
(BCCS) (p=027) (Figure 1C) and disease free survival (p<0.05) (Figure 1D).  In ER+/NPI 
>3.4 high risk breast cancer who received endocrine therapy, low DNA-PKcs expression 
remains significantly associated with worse breast cancer specific survival (BCCS) (p=048). 
On the other hand in ER+/NPI >3.4 high risk breast cancer who did not receive endocrine 
therapy, low DNA-PKcs did not influence BCSS although remained significant for DFS 
(p=0.044) (Figure 2A and 2B). 
 
DNA-PKcs protein expression in ER negative breast cancer: A total of 311 tumours were 
suitable for analysis. 122/311 of patients (39.2%) with ER negative breast cancer were 
classified as having low DNA-PKcs expression. Univariate associations between DNA-PKcs 
expression and clinicopathological variables are shown in Table 3.  Low DNA-PKcs 
expression was associated higher mitotic index (p=0.002), AR– (p=0.038), low XRCC1 
(P=0.003), low APE1 (p<0.0001), low polβ (p=0.017) and low p21 (p=0.01). Low DNA-Pkcs 
did not influence survival in ER negative tumours (Figure 2C and 2D).   
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DNA-PKcs mRNA expression in breast cancer:  A total of 1975 tumours were suitable for 
DNA-PKcs mRNA expression analysis.  1308/1975 (66.2%) tumours had low DNA-PKcs 
mRNA expression compared to 667/1975 (33.8%) tumours that had high DNA-PKcs mRNA 
expression. As shown in Table 5, low DNA-PKcs mRNA was significantly associated with 
PAM50.Her2 and  PAM50.Lum A molecular phenotypes (p<0.01). In contrast high DNA-
PKcs mRNA was significantly associated with PAM50.basal and PAM50.Lum B (p<0.01).  
In ER positive tumours (n=1496), low DNA-PKcs mRNA was associated with poor BCSS 
although with borderline significance (p=0.06). However, in ER positive patients who 
received adjuvant endocrine therapy (n=1216), low DNA-PKcs mRNA was significantly 
associated with poor BCSS (p=0.009). In ER negative tumours (n=437), low DNA-PKcs 
mRNA was significantly associated with poor BCSS (p=0.041). In addition, in ER negative 
patients who received adjuvant chemotherapy (n=416), low DNA-PKcs mRNA remains 
significantly associated with poor BCSS (p=0.009) 
Taken together the protein and mRNA expression data provides evidence that DNA-PKcs 
may have prognostic and predictive significance in breast cancer patients. 
 
DISCUSSION 
 
This is the first comprehensive study of DNA-PKcs expression in breast cancer. We found 
that low protein expression of DNA-PKcs was associated with adverse clinicopathological 
features including higher tumour grade, higher mitotic index, poorly differentiated and triple 
negative disease implying that impaired DNA-PKcs may be involved in breast cancer 
pathogenesis. Low DNA-PKcs was also linked to poor survival in univariate, as well as in 
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multivariate analysis, suggesting prognostic significance in patients. Interestingly, in ER 
positive tumours the prognostic significance was retained. Moreover, in patients who 
received endocrine therapy, low DNA-PKcs/ ER positive tumours were associated with poor 
breast cancer specific and disease free survival compared to high DNA-PKcs/ ER positive 
tumours that received endocrine therapy. Similarly at the mRNA level, low DNA-PKcs 
mRNA expression was associated with poor survival in patients who received endocrine 
therapy. This new observation suggests that DNA-PKcs may predict response to endocrine 
therapy.  Pre-clinically, the link between ER and DNA-PKcs has been reported {Medunjanin, 
2010 #415}. DNA-PKcs was shown to phosphorylate and stabilise ER and promote ER 
dependent transcriptional activity. Moreover, oestrogen was also shown to induce DNA-PKcs 
expression in breast cancer cells in that study. Together the authors suggested that reduced 
DNA-PKcs may be expected to attenuate oestrogen/ER induced proliferation signalling in 
breast cancer cells {Medunjanin, 2010 #415}. However, the data presented in our study 
contradicts the previous preclinical observation in that low DNA-PKcs was associated with 
aggressive breast cancer in our study implying that further mechanistic studies are required to 
investigate fully the functional link between DNA-PKcs and ER in breast cancer. Another 
possibility for the observed aggressive phenotype in human tumours is that low DNA-PKcs 
may be associated with, or reflect, genomic instability in cells. This is supported by the 
finding that low DNA-PKcs was significantly associated with low expression of several DNA 
repair proteins including BRCA1, XRCC1, SMUG1, APE1 and Polβ. Impaired DNA repair 
and the associated genomic instability may promote accelerated accumulation of mutations, 
resulting in a ‘mutator phenotype’ characterised by aggressive clinical behaviour {Loeb, 
2010 #428;Loeb, 2008 #444}. The clinicopathological associations seen in breast cancer in 
our study also concur with a study of DNA-PKcs expression in 564 gastric cancers {Lee, 
2007 #118;Lee, 2005 #149}. Negative DNA-PKcs was found in 20.2% of tumours and 
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associated with aggressive tumour and poor survival. Interestingly, frameshift mutation of 
(A)10 mononucleotide repeats in the DNA-PKcs gene was demonstrated in 24.3% of gastric 
cancers which was associated with higher risk of lymph node metastasis in that study {Lee, 
2007 #118;Lee, 2005 #149}. Whether a similar mechanism also operates in breast cancer is 
currently unknown and could be an area for future investigation. Moreover, a previous study 
conducted extensive profiling of DNA-PKcs mRNA and protein levels across normal and 
cancerous tissues {Moll, 1999 #567}. The authors demonstrated low DNA-PKcs protein was 
consistently low in breast cancer but no clinicopathological association data was reported. In 
normal tissues although there no significant changes at mRNA level, considerable variation 
were evident at the protein level in that study implying that DNA-PKcs protein expression 
was likely regulated at the post-transcriptional or post- translational level in that study{Moll, 
1999 #567}. Although the data presented in our study suggest that DNA-PKcs may regulated 
at the transcriptional level in breast cancer, whether additional mechanisms also operate is 
unknown. High resolution deep sequencing of the DNA-PKcs gene in a cohort of breast 
cancer could provide further insight. In ovarian cancers, similarly, low DNA-PKcs was 
associated with stage and lymph node metastasis {Shao, 2007 #568}. In contrast, in 
nasopharyngeal carcinoma, oesophageal cancer, colorectal cancer and lymphoid malignancies 
DNA-PKcs overexpression was associated with poor prognosis {Hsu, 2012 #572}. Taken 
together, the data suggest a complex role for DNA-Pkcs in different solid tumours.  
 
A surprising finding in the current study was that low DNA-PKcs mRNA in ER negative 
tumours (including in patients who received adjuvant chemotherapy) was associated with 
poor survival and at the protein level, although there was trend, it did not reach significance. 
This is in contrast to several pre-clinical reports that provide evidence that DNA-PKcs gene 
knock down or inhibition by small molecule inhibitors result in increased sensitivity to 
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chemotherapy and radiotherapy {Hsu, 2012 #253;Zhuang, 2011 #254;Du, 2010 
#256;Shinohara, 2005 #257}. Although intriguing, the data concurs with a recent report in a 
small cohort of breast cancers where high DNA-PKcs expression was associated with 
significant benefit from radiotherapy response in breast cancer patients {Soderlund Leifler, 
2010 #573}. The authors concluded that the role of proficient DNA-PKcs in p53 dependent 
pro-apoptotic response to cytotoxic therapy may have contributed to the observed 
effect{Soderlund Leifler, 2010 #573}. However, in our study we did not observe any 
associations with p53 expression in tumours.  Further mechanistic studies are required to 
clarify the role of DNA-PKcs in chemotherapy and radiotherapy response in human tumours.     
In conclusion we have shown that altered DNA-PKcs expression may influence pathogenesis 
and have prognostic and predictive significance in breast cancer. 
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Table 1. DNA-PKcs protein expression in  breast cancer  (whole cohort). 
   
 
                    VARIABLE 
 
DNA-PKcs PROTEIN EXPRESSION 
                   
 
 
P- value 
       Low 
n=404 
      High 
n= 757 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
32 (7.8%) 
198 (48.5%) 
166 (40.7%) 
12 (2.9%) 
 
80 (10.5%) 
380 (50.1%) 
284 (37.4%) 
15 (2.0%) 
 
0.268 
Tumour Stage                                 
1 
2 
3 
 
 
262 (63.9%) 
118 (28.8%) 
30 (7.3%) 
 
450 (59.2%) 
230 (30.3%) 
80 (10.5%) 
 
0.130 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
57 (14.0%) 
108 (26.5%) 
243 (59.6%) 
 
120 (15.8%) 
271 (35.7%) 
368 (48.5%) 
 
0.001 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
110 (27.2%) 
61 (15.1%) 
233 (57.7%) 
 
275 (36.4%) 
157 (20.8%) 
324 (42.9%) 
 
9.0x10-6 
Tubule Formation                          
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
16 (4.0%) 
111 (27.5%) 
277 (68.6%) 
 
40 (5.3%) 
268 (35.4%) 
448 (59.3%) 
 
0.008 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
6 (1.5%) 
145 (35.9%) 
253 (62.6%) 
 
20 (2.6%) 
278 (36.8%) 
458 (60.6%) 
 
0.403 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
232 (64.3%) 
54 (15.0%) 
12 (3.3%) 
25 (6.9%) 
38 (10.5%) 
 
382 (54.8%) 
136 (20.8%) 
12 (1.8%) 
65 (9.9%) 
59 (9.0%) 
 
0.031 
Lymphovascular Invasion                   
No 
Yes 
 
270 (66.5%) 
136 (33.5%) 
 
489 (65.0%) 
263 (35.0%) 
 
0.614 
B) Aggressive phenotype 
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Her2 overexpression                     
No 
Yes 
 
351 (88.2%) 
47 (11.8%) 
 
657 (88.2%) 
88 (11.8%) 
 
0.999 
Triple Negative Phenotype               
No 
Yes 
 
305 (77.8%) 
87 (22.2%) 
 
614 (82.5%) 
130 (17.5%) 
 
0.054 
Basal Like Phenotype           
No 
Yes 
 
329 (85.(%) 
54 (14.1%) 
 
637 (87.5%) 
91 (12.5%) 
 
0.452 
Cytokeratin 6 (CK6)                                  
Negative 
Positive 
298 (83.9%) 
57 (16.1%) 
 
529 (83.7%) 
103 (16.3%) 
 
0.921 
Cytokeratin 14 (CK14)                                                                     
Negative 
Positive 
297 (84.1%) 
56 (15.9%) 
552 (88.3%) 
73 (11.7%) 
 
0.063 
Cytokeratin 18 (CK18)                                   
Negative 
Positive 
45 (14.2%) 
272 (85.8%) 
 
 
50 (8.4%) 
544 (91.6%) 
 
0.007 
Cytokeratin 19 (CK19)                                   
Negative 
Positive 
32 (9.1%) 
319 (90.9%) 
 
27 (4.3%) 
602 (95.7%) 
 
0.002 
C) Hormone receptors 
 
ER               
Negative 
Positive 
 
127 (31.8%) 
272 (68.2%) 
 
192 (25.4%) 
563 (74.6%) 
 
0.021 
PgR                                   
Negative 
Positive 
 
176 (46.8%) 
200 (53.2%) 
 
294 (41.4%) 
416 (58.6%) 
 
0.087 
AR                     
Negative 
Positive 
 
 
154 (47.4%) 
171 (52.6%) 
 
190 (31.6%) 
412 (68.4%) 
 
0.0001 
D) DNA Repair 
 
BRCA1                     
Absent 
Normal 
 
67 (24.3%) 
209 (75.7%) 
 
99 (18.1%) 
447 (81.9%) 
 
0.038 
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XRCC1                             
Low 
High 
 
84 (27.4%) 
223 (72.6%) 
 
56 (10.1%) 
497 (89.9%) 
 
1.0x10-6 
FEN1                   
Low 
High 
 
239 (80.5%) 
58 (19.5%) 
 
360 (69.6%) 
157 (30.4%) 
 
0.001 
SMUG1                  
Low 
High 
 
 
128 (46.7%) 
146 (53.3%) 
 
 
161 (32.4%) 
336 (67.6%) 
 
8.4x10-5 
APE1 
Low 
High 
 
261 (72.7%) 
98 (27.3%) 
 
264 (39.5%) 
404 (60.5%) 
 
1.0x10-6 
PolB 
Low 
High 
 
 
201 (55.4%) 
162 (44.6%) 
 
196 (28.6%) 
490 (71.4%) 
 
1.0x10-6 
ATM  
Absent 
Present 
 
 
138 (54.3%) 
116 (45.7%) 
 
246 (54.1%) 
209 (45.9%) 
 
0.946 
E) Cell cycle/apoptosis regulators 
 
P16 
Low 
High 
 
247 (79.9%) 
62 (20.1%) 
 
460 (89.7%) 
53 (10.3%) 
 
9.8x10-5 
P21 
Low 
High 
 
198 (62.7%) 
118 (37.3%) 
 
287 (53.8%) 
246 (46.2%) 
 
0.012 
MIB1                       
Low 
High 
 
97 (29.7%) 
230 (70.3%) 
 
218 (34.1%) 
422 (65.9%) 
 
0.167 
P53              
Low expression 
High expression 
           
 
256 (77.3%) 
75 (22.7%) 
 
490 (78.7%) 
133 (21.3%) 
 
0.641 
Bcl-2                            
Negative 
Positive 
 
233 (34.6%) 
441 (65.4%) 
 
378 (36.0%) 
673 (64.0%) 
 
0.207 
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TOP2A                    
Low 
Overexpression 
 
 
156 (52.5%) 
141 (47.5%) 
 
229 (41.6%) 
321 (58.4%) 
 
0.002 
Bold= statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human 
epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: 
cytokeratin; Basal-like: ER-, HER2- and positive expression of either CK5/6, CK14 or 
EGFR; Triple negative: ER-/PgR-/HER2- 
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Table 2. DNA-PKcs and ER positive breast cancer  
   
 
                    VARIABLE 
 
DNA-PKcs PROTEIN EXPRESSION 
                   
 
 
P- value 
       Low 
n= 272 
      High 
n= 563 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
23 (8.5%) 
137 (50.7%) 
105 (38.9%) 
5 (1.9%) 
 
65 (11.6%) 
293 (52.1%) 
195 (34.7%) 
9 (1.6%) 
 
0.453 
Tumour Stage                                 
1 
2 
3 
 
 
167 (61.4%) 
87 (32.0%) 
18 (6.6%) 
 
338 (60.1%) 
173 (30.8%) 
51 (9.1%) 
 
0.479 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
51 (18.9%) 
96 (35.6%) 
123 (45.6%) 
 
111 (19.8%) 
249 (44.3%) 
202 (35.9%) 
 
0.021 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
104 (38.7%) 
53 (19.7%) 
112 (41.6%) 
 
255 (45.5%) 
131 (23.4%) 
175 (31.2%) 
 
0.013 
Tubule Formation                          
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
14 (5.2%) 
87 (32.3%) 
168 (62.5%) 
 
36 (6.4%) 
237 (42.2%) 
288 (51.3%) 
 
0.011 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
6 (2.2%) 
131 (48.7%) 
132 (49.1%) 
 
17 (3.0%) 
261 (46.5%) 
283 (50.4%) 
 
0.715 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
142 (56.8%) 
47 (18.8%) 
3 (1.2%) 
22 (8.8%) 
36 (14.4%) 
 
248 (50.4%) 
131 (26.6%) 
1 (0.2%) 
59 (12.0%) 
53 (10.8%) 
 
0.018 
Lymphovascular Invasion                   
No 
Yes 
 
177 (65.6%) 
93 (34.4%) 
 
362 (64.9%) 
196 (35.1%) 
 
0.847 
B) Aggressive phenotype 
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Her2 overexpression                     
No 
Yes 
 
249 (93.6%) 
17 (6.4%) 
 
511 (92.6%) 
41 (7.4%) 
 
0.588 
Cytokeratin 6 (CK6)                                  
Negative 
Positive 
229 (94.2%) 
14 (5.8%) 
 
454 (94.4%) 
27 (5.6%) 
 
0.935 
Cytokeratin 14 (CK14)                                                                     
Negative 
Positive 
220 (90.9%) 
22 (9.1%) 
444 (93.5%) 
31 (6.5%) 
 
0.215 
Cytokeratin 18 (CK18)                                   
Negative 
Positive 
10 (4.5%) 
214 (95.5%) 
 
8 (1.8%) 
444 (98.2%) 
 
0.041 
Cytokeratin 19 (CK19)                                   
Negative 
Positive 
11 (4.6%) 
229 (95.4%) 
 
16 (3.3%) 
462 (96.7%) 
 
0.411 
C) Hormone receptors 
 
PgR                                   
Negative 
Positive 
 
59 (23.1%) 
196 (76.9%) 
 
117 (22.0%) 
415 (78.0%) 
 
0.718 
AR                     
Negative 
Positive 
 
 
74 (32.9%) 
151 (67.1%) 
 
96 (20.8%) 
366 (79.2%) 
 
0.001 
D) DNA Repair 
 
BRCA1                     
Absent 
Normal 
 
38 (19.3%) 
159 (80.7%) 
 
54 (13.1%) 
359 (86.9%) 
 
0.045 
XRCC1                             
Low 
High 
 
46 (22.3%) 
160 (77.7%) 
 
29 (7.0%)  
388 (93.0%) 
 
 
1.0x10-6 
 
FEN1                   
Low 
High 
 
163 (81.1%) 
38 (18.9%) 
 
265 (68.1%) 
124 (31.9%) 
 
0.001 
SMUG1                  
Low 
High 
 
 
78 (42.9%) 
104 (57.1%) 
 
97 (26.4%) 
271 (73.6%) 
 
9.3x10-5 
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APE1 
Low 
High 
 
169 (71.0%) 
69 (29.0%) 
 
186 (36.9%) 
318 (63.1%) 
 
1.0x10-6 
 
PolB 
Low 
High 
 
 
122 (50.8%) 
118 (49.2%) 
 
115 (22.5%) 
397 (77.5%) 
 
1.0x10-6 
 
ATM  
Absent 
Present 
 
 
84 (49.7%) 
85 (50.3%) 
 
 
174 (51.2%) 
166 (48.8%) 
 
0.754 
E) Cell cycle/apoptosis regulators 
 
P16 
Low 
High 
 
190 (92.2%) 
16 (7.8%) 
 
368 (98.1%) 
7 (1.9%) 
4.8x10-4 
 
P21 
Low 
High 
 
114 (53.5%) 
99 (46.5%) 
 
193 (48.9%) 
202 (51.1%) 
 
0.273 
MIB1                       
Low 
High 
 
84 (38.0%) 
137 (62.0%) 
 
196 (40.8%) 
284 (59.2%) 
 
0.478 
P53              
Low expression 
High expression 
           
 
202 (87.8%) 
28 (12.2%) 
 
412 (87.3%) 
60 (12.7%) 
 
0.840 
Bcl-2                            
Negative 
Positive 
 
59 (22.8%) 
200 (77.2%) 
 
110 (21.6%) 
400 (78.4%) 
 
0.701 
TOP2A                    
Low 
Overexpression 
 
 
106 (55.5%) 
85 (44.5%) 
 
171 (41.9%) 
237 (58.1%) 
 
0.002 
Bold= statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human 
epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: 
cytokeratin; Basal-like: ER-, HER2- and positive expression of either CK5/6, CK14 or 
EGFR; Triple negative: ER-/PgR-/HER2- 
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Table 3. DNA-PKcs and ER negative breast cancer  
   
 
                    VARIABLE 
 
DNA-PK PROTEIN EXPRESSION 
                   
 
 
P- value 
       Low 
n= 122 
      High 
n= 189 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
8 (6.3%) 
55 (43.3%) 
58 (45.7%) 
6 (4.7%) 
 
13 (6.8%) 
83 (43.7%) 
88 (46.3%) 
6 (3.2%) 
 
0.911 
Tumour Stage                                 
1 
2 
3 
 
 
85 (66.9%) 
30 (23.6%) 
12 (9.4%) 
 
 
107 (56.0%) 
55 (28.8%) 
29 (15.2%) 
 
0.122 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
2 (1.6%) 
8 (6.3%) 
117 (92.1%) 
 
6 (3.2%) 
19 (10.0%) 
165 (86.8%) 
 
0.330 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
3 (2.4%) 
6 (4.8%) 
117 (92.9%) 
 
16 (8.5%) 
25 (13.2%) 
148 (78.3%) 
 
0.002 
Tubule Formation                          
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
1 (0.8%) 
19 (15.1%) 
106 (84.1%) 
 
2 (1.1%) 
30 (15.9%) 
157 (83.1%) 
 
0.953 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
0 (0.0%) 
9 (7.1%) 
117 (92.9%) 
 
1 (0.5%) 
15 (7.9%) 
173 (91.5%) 
 
0.690 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
87 (82.1%) 
6 (5.7%) 
9 (8.5%) 
3 (2.8%) 
1 (0.9%) 
 
132 (84.1%) 
3 (1.9%) 
11 (7.0%) 
5 (3.2%) 
6 (3.8%) 
 
0.307 
24	  
	  
Lymphovascular Invasion                   
No 
Yes 
 
84 (66.7%) 
42 (33.3%) 
 
122 (65.2%) 
65 (34.8%) 
 
0.794 
B) Aggressive phenotype 
 
Her2 overexpression                     
No 
Yes 
 
94 (75.8%) 
30 (24.2%) 
 
140 (74.9%) 
47 (25.1%) 
 
0.851 
Triple Negative Phenotype               
No 
Yes 
 
31 (26.3%) 
87 (73.7%) 
 
49 (27.4%) 
130 (72.6%) 
 
0.834 
Basal Like Phenotype           
No 
Yes 
 
55 (50.5%) 
54 (49.5%) 
 
73 (44.5%) 
91 (55.5%) 
 
0.335 
Cytokeratin 6 (CK6)                                  
Negative 
Positive 
66 (61.7%) 
41 (38.3%) 
 
73 (49.0%) 
76 (51.0%) 
 
0.044 
Cytokeratin 14 (CK14)                                                                     
Negative 
Positive 
75 (70.1%) 
32 (29.9%) 
 
107 (71.8%) 
42 (28.2%) 
 
0.765 
Cytokeratin 18 (CK18)                                   
Negative 
Positive 
34 (37.0%) 
58 (63.0%) 
 
42 (30.0%) 
98 (70.0%) 
 
0.269 
Cytokeratin 19 (CK19)                                   
Negative 
Positive 
21 (19.8%) 
85 (80.2%) 
 
11 (7.3%) 
139 (92.7%) 
 
0.003 
C) Hormone receptors 
 
PgR                                   
Negative 
Positive 
 
115 (98.3%) 
2 (1.7%) 
 
177 (100%) 
0 (0.0%) 
 
 
0.081 
AR                     
Negative 
Positive 
 
 
79 (79.8%) 
20 (20.2%) 
 
94 (67.6%) 
45 (32.4%) 
 
0.038 
D) DNA Repair 
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BRCA1                     
Absent 
Normal 
 
29 (36.7%) 
50 (63.3%) 
 
45 (34.1%) 
87 (65.9%) 
 
0.700 
XRCC1                             
Low 
High 
 
36 (38.3%) 
58 (61.7%) 
 
27 (20.5%) 
105 (79.5%) 
 
0.003 
FEN1                   
Low 
High 
 
69 (78.4%) 
19 (21.6%) 
 
94 (75.2%) 
31 (24.8%) 
 
0.586 
SMUG1                  
Low 
High 
 
 
48 (57.1%) 
36 (42.9%) 
 
64 (50.8%) 
62 (49.2%) 
 
0.366 
APE1 
Low 
High 
 
84 (75.7%) 
27 (24.3%) 
 
75 (47.5%) 
83 (52.5%) 
 
4.0x10-6 
 
PolB 
Low 
High 
 
 
69 (61.9%) 
43 (38.4%) 
 
79 (47.0%) 
89 (53.0%) 
 
 
0.017 
ATM  
Absent 
Present 
 
 
54 (64.3%) 
30 (35.7%) 
 
71 (62.3%) 
43 (37.7%) 
 
0.773 
E) Cell cycle/apoptosis regulators 
 
P16 
Low 
High 
 
53 (54.6%) 
44 (45.4%) 
 
 
90(66.7%) 
45 (33.3%) 
 
 
0.063 
P21 
Low 
High 
 
81 (82.7%) 
17 (17.3%) 
 
90 (67.7%) 
43 (32.3%) 
 
0.010 
 
MIB1                       
Low 
High 
 
11 (11.0%) 
89 (89.0%) 
 
 
22 (14.0%) 
135 (86.0%) 
 
0.482 
P53              
Low expression 
High expression 
           
 
53 (53.0%) 
47 (47.0%) 
 
75 (50.7%) 
73 (49.3%) 
 
0.719 
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Bcl-2                            
Negative 
Positive 
 
84 (75.7%) 
27 (24.3%) 
 
122 (76.7%) 
37 (23.3%) 
 
 
0.841 
TOP2A                    
Low 
Overexpression 
 
 
46 (45.5%) 
55 (54.5%) 
 
58 (42.3%) 
79 (57.7%) 
 
0.622 
Bold= statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human 
epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: 
cytokeratin; Basal-like: ER-, HER2- and positive expression of either CK5/6, CK14 or 
EGFR; Triple negative: ER-/PgR-/HER2- 
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Table 4.  Multivariate analysis in breast cancer.  
 
 P Value Exp (B) 95% CI of Exp(B) 
Lower Upper 
Disease Free Survival 
 
DNA-PKcs (low protein)       6.7x10-5 0.886 0.834 0.940 
Stage       1.0x10-6 1.728 1.515 1.971 
Grade        2.9x10-4 1.270 1.116 1.446 
Size        4.0x10-3 1.130 1.039 1.230 
Breast Cancer Specific Survival 
 
DNA-PKcs (low protein)  4.0x10-3 0.901 0.839 0.968 
Stage  1.0x10-6 1.936 1.661 2.256 
Grade  1.0x10-6 2.005 1.672 2.404 
Size   5.0x10-3 1.157 1.045 1.281 
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Table 5: Association between DNA-PKcs mRNA expression and molecular phenotypes. 
PAM50 subtype DNA-PKc mRNA Expression  
 
X2 
 
Adjusted p value 
Low  
 N=1308 
(66.23%) 
 
    High  
N= 667  
(33.77%) 
 
 
PAM50.Her2 166(14.70%) 72(11.20%) 0.040 
PAM50.Basal   156(13.80%) 174(27.10%) 4.25×10-12 
PAM50.LumA 545(48.20%) 169(26.40%) 1.98×10-19 
PAM50.LumB 263(23.30%) 226(35.30%) 5.94×10-08 
 
